Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoTPE:6472 -0.88%83 3-Year ROIIC % is 6.78 as of Dec. 2025, which is 39% below its 10-year median of 11.08. GuruFocus rates TPE:6472 with a GF Score™ of 83/100 and a GF Value™ of NT$736.58 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 55.39% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Bora Pharmaceuticals Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 6.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Bora Pharmaceuticals Co's 3-Year ROIIC % or its related term are showing as below:
TPE:6472's 3-Year ROIIC % is ranked better than 55.39% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs TPE:6472: 6.78
Bora Pharmaceuticals Co (TPE:6472) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Bora Pharmaceuticals Co 3-Year ROIIC % Related Terms
Bora Pharmaceuticals Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Bora Pharmaceuticals Co (TPE:6472) has a 3-Year ROIIC % of 6.78 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bora Pharmaceuticals Co and its competitors. This is 39% below median its historical median of 11.08. Over the past decade, Bora Pharmaceuticals Co's 3-Year ROIIC % has ranged from 1.86 to 27.06. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #422 out of 946 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Bora Pharmaceuticals Co's 3-Year ROIIC % too high?
Bora Pharmaceuticals Co's current 3-Year ROIIC % of 6.78 is 39% below median its 10-year median of 11.08. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 27.06. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Bora Pharmaceuticals Co's value of 6.78 is 86.5% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #422 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #422 out of 946 companies for 3-Year ROIIC %. This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Bora Pharmaceuticals Co's value of 6.78 is 86.5% above this benchmark. Historically, Bora Pharmaceuticals Co's own 3-Year ROIIC % has ranged from 1.86 to 27.06 over the past decade. While the company's 10-year median is 11.08 vs. the industry median of 3.64, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current 3-Year ROIIC % of 6.78 is 86.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current 3-Year ROIIC % is 6.78, which is 39% below median its own 10-year median of 11.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$736.58, compared to a current price of NT$392.50 — trading 46.7% below its estimated fair value. The current 3-Year ROIIC % is 6.78, which is 39% below median its 10-year median of 11.08 and 86.5% above the Drug Manufacturers industry median of 3.64. Bora Pharmaceuticals Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current 3-Year ROIIC % is 6.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$392.50 is trading 46.7% below its estimated GF Value™ of NT$736.58.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
3-Year ROIIC %: 6.78 (39% below median its 10-year median of 11.08)
GF Value™: NT$736.58 vs. price of NT$392.50 (46.7% below fair value)
Industry Position: 86.5% above the Drug Manufacturers median (#422 of 946)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
83GF Score
Get the complete analysis for TPE:6472
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
